Research presented at the European Association for the Study of Diabetes meeting provides reassuring evidence that semaglutide does not increase pancreatic cancer risk, addressing longstanding safety concerns around the drug class.
New research presented at the European Association for the Study of Diabetes meeting in Milan has found no evidence that semaglutide raises the risk of pancreatic cancer, adding fresh weight to a safety question that has shadowed the blockbuster diabetes and weight-loss drug class. The study, led by Anton Pottegård of the University of Southern Denmark, used nationwide registry data from Denmark, Sweden and Norway and compared new semaglutide users with people starting other glucose-lowering medicines at a similar point in treatment.
The analysis was designed as a regulator-requested post-authorisation safety study, reflecting longstanding concern that incretin-based drugs, including GLP-1 receptor agonists, might somehow affect the pancreas. That concern grew out of early adverse-event reports and animal studies, but the new data did not support a cancer signal. Among nearly 97,500 semaglutide users, researchers identified 131 pancreatic cancer cases, versus 123 cases in the matched comparison group, and pooled results showed no increased risk overall.
The findings were consistent across the three countries and across a range of sensitivity checks. There was no sign of a dose-response pattern, and longer exposure did not appear to increase risk. The pooled estimate pointed to no meaningful difference in pancreatic cancer incidence between semaglutide users and matched patients taking sulfonylureas, SGLT-2 inhibitors or insulin.
The new registry study is also in line with earlier evidence. A meta-analysis of randomised trials published in September 2026 found no significant increase in pancreatic cancer risk with semaglutide, while a 2023 systematic review and meta-analysis of 37 studies involving 46,719 patients likewise found no elevated risk. Even so, researchers have cautioned that the question has been difficult to settle definitively because pancreatic cancer is relatively rare, long-term follow-up remains limited, and people taking semaglutide often already have obesity or type 2 diabetes, both of which are themselves linked to higher cancer risk.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
